Cytek BioSciences, Inc. is listed today as Cytek Biosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2020 | $120 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Cytek Biosciences, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $201.49 million (100%).
Annual report (SEC XBRL) · Dec 2025
Cytek BioSciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).
SEC Form D · Nov 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2020
Products and services#
No products or services of Cytek BioSciences, Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series D preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, director (Form 3, 2021) | SEC Form 3 |
| RA Capital Nexus Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 14 investors.
Largest shareholders today
Institutions holding Cytek Biosciences, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$73 M9.32%
- Millennium Management LLC$43 M5.57%
- Hhlr Advisors, LTD.$40 M5.09%
- Boston Partners$39 M4.99%
- Topline Capital Management, LLC$39 M4.99%
- Vanguard Capital Management LLC$29 M3.74%
- Geode Capital Management, LLC$18 M2.35%
- Acadian Asset Management LLC$16 M2.08%
- Dimensional Fund Advisors LP$15 M1.96%
- State Street Corp$15 M1.95%
- Russell Investments Group, Ltd.$14 M1.86%
- Goldman Sachs Group Inc$14 M1.78%
- Royce & Associates LP$12 M1.59%
- Arrowstreet Capital, Limited Partnership$12 M1.56%
- Bank Of America Corp /de/$10 M1.24%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ming Yan | Executive officer | Nov 2020 |
| Wenbin Jiang | Executive officer | Nov 2020 |
| Allen Poirson | Director | Nov 2020 |
| Andrew Levin | Director | Nov 2020 |
| Feng Deng | Director | Nov 2020 |
| Jack Ball | Director | Nov 2020 |
| Jiecheng Zhang | Director | Nov 2020 |
| Ming Yan | Director | Nov 2020 |
| Wenbin Jiang | Director | Nov 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.